Dermata Therapeutics, Inc.

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in Dermata Therapeutics, Inc..

News

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Accesswire SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ('Dermata' or the 'Company'), a late-stage biotechnology company focusing on the treatment of medical...\n more…

Maxim Group Lowers Dermata Therapeutics (NASDAQ:DRMA) Price Target to $6.00

Ticker Report Dermata Therapeutics (NASDAQ:DRMA - Get Free Report) had its target price lowered by equities researchers at Maxim Group from $10.00 to $6.00 in a note issued to investors on Wednesday, Benzinga...\n more…

Dermata Therapeutics (NASDAQ:DRMA) PT Lowered to $6.00

Zolmax Dermata Therapeutics (NASDAQ:DRMA - Get Free Report) had its target price dropped by Maxim Group from $10.00 to $6.00 in a research note issued to investors on Wednesday, Benzinga reports. The...\n more…

Dermata Therapeutics price target lowered by $4 at Maxim, here's why

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nDRMA stock results show that Dermata Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.\nThe post...\n more…

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results

Accesswire - DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial has enrolled over 50% of patients- Dermata continues discussions with potential botulinum toxin partners for DMT410...\n more…